Protectus Medical Devices, Inc. (OTCQB: PTMD) (PINKSHEETS: PTMD), a developer and marketer of innovative safety medical devices, announces that the Company's CEO Dr. John Salstrom, will begin a series of one-on-one interviews with OTC Voice.com

Protectus' CEO, John Salstrom, Ph.D., said, "We will begin this series of interviews by discussing the unique technological advantages the Protectus Safety Syringe has over competitors' products and the reasons we see Protectus Medical Devices as a Company investors should watch."

Dr. Salstrom stated, "Through the course of this series of interviews, together with Jack Dillard, COO and inventor of the Protectus Safety Syringe, we will be discussing the most recent patent granted to Protectus by the US Patent Office, as well as any of the Company's new patent filings covering future products, developments with our national distributor, annual growth of the safety syringe market, the continuing plague of needlestick injuries, both in the US and internationally, and international developments for Protectus Medical Devices."

The family of Protectus devices, including its lead product, the Protectus Safety Syringe, the two Safety Dental Syringes, the Safety IV Catheter and the Safety Phlebotomy Device, should prevent needlestick injuries and save the lives of doctors, nurses and healthcare workers across the nation and worldwide, thereby contributing to the significant reduction of healthcare costs stemming from accidental needlestick injuries in the United States and around the world.

To access this first interview please click on the link below.

www.OTCVoice.com.

About Protectus Medical Devices, Inc.

Protectus Medical Devices, Inc. (OTCQB: PTMD) (formerly E-18 Corp.), operating through its wholly owned subsidiary, SquareOne Medical, Inc., develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. In the nearly $5 billion global hypodermic syringe market, the Protectus Safety Syringe, the Company's lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of "Self-sheathing" mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim. Protectus Medical Devices has successfully patented its automatic, self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at www.protectusmedical.com.

Forward-Looking Statements

This release contains "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. These forward-looking statements are subject to various risks and uncertainties that could cause the business and financial results of Protectus Medical Devices, Inc. to differ materially from those currently anticipated, including the risk factors identified in the filings of Protectus Medical Devices, Inc. with the Securities and Exchange Commission.

Contact:

John S. Salstrom, Ph.D.
President and CEO
Protectus Medical Devices, Inc.
1-800-778-8438
moreinfo@protectusmedical.com
The Investor Relations Group
212-825-3210
Adam Holdsworth or James Carbonara